Last reviewed · How we verify
Conjugated equine estrogen topical cream
Conjugated equine estrogen topical cream delivers estrogen directly to vaginal and vulvar tissues to relieve menopausal symptoms such as vaginal atrophy and dryness.
Conjugated equine estrogen topical cream delivers estrogen directly to vaginal and vulvar tissues to relieve menopausal symptoms such as vaginal atrophy and dryness. Used for Vaginal atrophy and dryness associated with menopause, Genitourinary syndrome of menopause (GSM).
At a glance
| Generic name | Conjugated equine estrogen topical cream |
|---|---|
| Also known as | Premarin vaginal cream, Vaginal estrogen cream, CEE topical cream |
| Sponsor | University of Louisville |
| Drug class | Topical hormone replacement therapy; estrogen |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Gynecology; Menopause |
| Phase | FDA-approved |
Mechanism of action
The cream contains a mixture of estrogen compounds derived from pregnant mare urine, which are absorbed through the vaginal epithelium. These estrogens bind to estrogen receptors in vaginal and vulvar tissues, promoting epithelial proliferation, increasing blood flow, and restoring moisture and elasticity to atrophic tissues. This localized hormone replacement therapy alleviates symptoms of genitourinary syndrome of menopause without requiring systemic absorption.
Approved indications
- Vaginal atrophy and dryness associated with menopause
- Genitourinary syndrome of menopause (GSM)
Common side effects
- Vaginal irritation or burning
- Headache
- Breast tenderness
- Vaginal bleeding or spotting
Key clinical trials
- Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis (PHASE1)
- Vaginal and Urinary Microbiome Trial (PHASE4)
- Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: